Updated on 19 October 2026
CLOUDSCREEN
Project Manager / Biomedical Scientist at Cloudpharm P.C
Athens, Greece
About
A ligand-protein target based drug repurposing platform, using ML and advanced molecular modelling approaches on multi-source data, covering molecular representations of the entire human proteome as well as and all authorized pharmaceutical substances along with clinical studies and patents connected to them.
Currently at TRL 4, we are interested in joining collaborative research and innovation consortia involving partners from complementary and broader interdisciplinary fields, where CLOUDSCREEN can both contribute to shared objectives and be further advanced through new research and development activities.
Drug repositioning is identified as a recommended activity in HORIZON-MISS-2027-02-CANCER-03. In this context, CLOUDPHARM’s ligand–target interaction modelling could support the identification and prioritisation of existing drugs with potential activity against molecularly defined rare cancers, particularly those driven by specific protein defects.
We welcome discussions with potential partners interested in building interdisciplinary projects around shared scientific, technological and societal challenges.
Similar opportunities
Project cooperation
Fusing AI/ML with cheminformatics modelling into project concepts
Evangelia-Mantelena Makri
Project Manager / Biomedical Scientist at Cloudpharm P.C
Athens, Greece
Project cooperation
Dr Raphaël Duval
CEO at THERIOPHARM
Wavre, Belgium
Project cooperation
New Generation Switchable Living Drugs
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Ilaria PITTON
Research Facilitator at Ca'Foscari University of Venice
Venice, Italy